Conformation-Specific Lambda Monoclonal Antibodies for Amyloid Clearance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for AL amyloidosis, such as daratumumab and autologous stem cell transplants, target the underlying plasma cell dyscrasia but do not directly address the existing amyloid deposits affecting organs, particularly in late-stage cardiac disease, posing a significant challenge in improving organ function.

Innovation Solution

Development of anti-human lambda light chain antibodies that specifically bind to misfolded lambda light chains, promoting their clearance and reducing amyloid deposits, thereby treating or diagnosing AL amyloidosis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments (daratumumab, autologous stem cell transplants) target plasma cell dyscrasia, then the underlying disease mechanism is addressed, but existing amyloid deposits affecting organs are not directly cleared

Engineering Contradiction:

Improveeffectiveness of treating underlying plasma cell dyscrasiaVSAvoidability to directly clear existing amyloid deposits

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The treatment approach is segmented into two distinct functions: (1) existing therapies continue to address plasma cell dyscrasia, while (2) the new anti-lambda light chain antibodies specifically target and clear amyloid deposits. This segmentation allows both objectives to be achieved simultaneously without interfering with each other's mechanisms of action.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The anti-lambda light chain antibodies serve as an intermediary agent that bridges the gap between treating the underlying plasma cell dyscrasia and clearing existing amyloid deposits. These antibodies specifically bind to misfolded lambda light chains in amyloid deposits, facilitating their clearance by immune cells without affecting plasma cell function directly.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If anti-light chain antibodies target variable regions, then they bind to light chains, but different patients produce light chains with different amino acid sequences resulting in inconsistent binding

Engineering Contradiction:

Improvebinding capability to light chainsVSAvoidconsistency of binding across different patients

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The antibody is designed to recognize a universal epitope in the constant region of lambda light chains that is conserved across all lambda light chain sequences. This universal binding site allows the same antibody to consistently bind to lambda light chains from different patients regardless of variations in their variable regions, ensuring reliable and consistent therapeutic effect.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Measurement precision

If antibodies bind to properly folded light chains, then they can detect light chains, but they cause unwanted immunological side-effects and sequestration of therapeutic antibody

Engineering Contradiction:

Improvedetection capability of light chainsVSAvoidimmunological side-effects and off-target binding

Core Design Contradiction:

Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The antibody exhibits different binding properties at different locations on the light chain molecule: it binds with high affinity to misfolded lambda light chains in amyloid deposits (pathological state) while showing minimal or no binding to properly folded lambda light chains (normal state). This location-specific binding quality allows selective clearance of amyloid deposits without causing off-target effects or sequestration of therapeutic antibodies by normal proteins.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The antibodies effectively clear misfolded lambda light chains, reducing amyloid deposits and improving organ function without depleting plasma cell populations, offering a non-invasive therapy for late-stage AL amyloidosis.

Implementation Method 1

anti-human lambda light chain antibodies that specifically bind to misfolded lambda light chains

Methodology Applied

Scientific EffectAntigen-antibody binding:

Data Source

PatentUS20250326864A1Monoclonal antibodies targeting conformation-specific epitopes of immunoglobulin light chains of the lambda subclass

Publication Date: 2025.10.23 PARADOX IMMUNOTHERAPEUTICS INC

AI summary

Provided herein are anti-human λ light chain antibodies or human λ light chain binding antibody fragments that bind an epitope specific of the human λ light chain. Also provided are polynucleotides and vectors encoding the same, and compositions comprising anti-human λ light chain antibodies or human λ light chain binding antibody fragments. The anti-human λ light chain antibodies or human λ light chain binding antibody fragments are useful for measuring human λ light chain in a biological sample comprising contacting the sample with the anti-human λ light chain antibodies or human λ light chain binding antibody fragments. The anti-human λ light chain antibodies or human λ light chain binding antibody fragments are also useful for reducing λ light chain aggregates.